MSD K.K., the Japan unit of US pharma giant Merck, is to launch a voluntary redundancy program to shed 250 employees in a bid to cope with its changing product portfolios. A MSD spokesperson told Jiho on August 30 that…
To read the full story
Related Article
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
BUSINESS
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…





